RLFTF (Relief Therapeutics Holding) Net Margin %: -367.62% (As of Jun. 2025)


RLFTF Relief Therapeutics Holding SA RLFTF
31 GF Score
Price $0.29
GF Value $0.61
! 5 Warning Signs
View Full Analysis

What is Relief Therapeutics Holding Net Margin %?

Relief Therapeutics Holding RLFTF +0.56% 31 Net Margin % is -367.62% as of Jun. 2025. GuruFocus rates RLFTF with a GF Score™ of 31/100 and a GF Value™ of $0.61. The stock has 5 warning signs investors should review.

Net margin is calculated as Net Income divided by its Revenue. Relief Therapeutics Holding's Net Income for the six months ended in Jun. 2025 was $-5.51 Mil. Relief Therapeutics Holding's Revenue for the six months ended in Jun. 2025 was $1.50 Mil. Therefore, Relief Therapeutics Holding's net margin for the quarter that ended in Jun. 2025 was -367.62%.

The historical rank and industry rank for Relief Therapeutics Holding's Net Margin % or its related term are showing as below:

RLFTF' s Net Margin % Range Over the Past 10 Years
Min: -112226.67   Med: -940.12   Max: -77.17
Current: -420.33

RLFTF's Net Margin % is not ranked
in the Biotechnology industry.
Industry Median: -89.56 vs RLFTF: -420.33

Relief Therapeutics Holding  (OTCPK:RLFTF) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Relief Therapeutics Holding Net Margin % Related Terms

Relief Therapeutics Holding Net Margin % Historical Data

* Premium members only.

The historical data trend for Relief Therapeutics Holding's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Relief Therapeutics Holding Net Margin % Chart

Relief Therapeutics Holding Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Net Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 -1,044.98 -835.28 -1,627.44 -203.39

Relief Therapeutics Holding Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1,869.20 -1,384.60 -81.65 -442.91 -367.62

RLFTF vs KTTA, OSRH, LIMN: Net Margin % Comparison

For the Biotechnology subindustry, Relief Therapeutics Holding's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Relief Therapeutics Holding Net Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Relief Therapeutics Holding's Net Margin % distribution charts can be found below:

* The bar in red indicates where Relief Therapeutics Holding's Net Margin % falls into.


RLFTF
31GF Score
Relief Therapeutics Holding SA RLFTF
Net Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Relief Therapeutics Holding Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Relief Therapeutics Holding's Net Margin for the fiscal year that ended in Dec. 2024 is calculated as

Net Margin=Net Income (A: Dec. 2024 )/Revenue (A: Dec. 2024 )
=-19.2/9.44
=-203.39 %

Relief Therapeutics Holding's Net Margin for the quarter that ended in Jun. 2025 is calculated as

Net Margin=Net Income (Q: Jun. 2025 )/Revenue (Q: Jun. 2025 )
=-5.507/1.498
=-367.62 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of -367.62% mean?
Relief Therapeutics Holding (RLFTF) has a Net Margin % of -367.62% as of Jun. 2025. Net margin is the ratio of total net income to net sales. View historical data on Relief Therapeutics Holding and its competitors.
Is Relief Therapeutics Holding's Net Margin % too high?
Relief Therapeutics Holding's current Net Margin % is -367.62%. Overall, Relief Therapeutics Holding has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Relief Therapeutics Holding's Net Margin % compare to KTTA and OSRH?
Relief Therapeutics Holding's Net Margin % of -367.62% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Relief Therapeutics Holding and its competitors. Relief Therapeutics Holding's current Net Margin % is -367.62%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Relief Therapeutics Holding stock overvalued right now?
Relief Therapeutics Holding (RLFTF) has a current Net Margin % of -367.62%. The stock's GF Value™ is $0.61, compared to a current price of $0.29 — trading 53.3% below its estimated fair value. The current Net Margin % is -367.62%. Relief Therapeutics Holding's overall GF Score™ is 31/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Relief Therapeutics Holding (RLFTF), the current Net Margin % is -367.62% as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Relief Therapeutics Holding (RLFTF) Overvalued in 2026?

Based on GuruFocus' analysis, Relief Therapeutics Holding stock appears to be undervalued. The current stock price of $0.29 is trading 53.3% below its estimated GF Value™ of $0.61.

Key valuation signals for RLFTF:

  • Net Margin %: -367.62%
  • GF Value™: $0.61 vs. price of $0.29 (53.3% below fair value)
  • GF Score™: 31/100 with 5 warning signs

No single metric tells the full story. See the RLFTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Relief Therapeutics Holding Business Description

Address Avenue de Secheron 15, Geneva, CHE, 1202
Relief Therapeutics Holding SA is engaged in the research, development, and commercialization of biopharmaceutical products. It mainly develops drugs of natural human origin. It has a focus on commercial products, and the development program pipeline is focused on three main areas: rare genetic, metabolic disorders, rare connective tissue disorders, and rare lung diseases. Its pipeline includes various drug candidates in their different stages of development, such as RLF-TD011 and RLF-100, among others. It also has commercial legacy products like Cambia, Setofilm, Voltadol, and Voltfast, among others. Geographically, the company generates a majority of its revenue from Europe (excluding Switzerland) and the rest from North America, Switzerland, and the rest of the world.
31GF Score

Get the complete analysis for RLFTF

Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.29
Price
$0.61
GF Value